SA
HURA

S&P 500, Nasdaq, Russell 2000 below the 200-day average · VIX 35.9 · very high volatility

Overview →
11/22/26

TuHURA Biosciences (HURA)

Sunday
1:57 AM ET
ThesisTuHURA Biosciences: the story is balanced — Clinical trial data releases - particularly efficacy signals (ORR, PFS) and safety profiles from ongoing Phase 1/2…

Revenue Outlook

★ Analysts see FY2027 revenue reaching $17M — +60.7% growth in a single year.

What Moves the Stock

  1. 01Clinical trial data releases - particularly efficacy signals (ORR, PFS) and safety profiles from ongoing Phase 1/2 studies
  2. 02Cash position updates and financing announcements - dilutive equity raises, PIPE transactions, or strategic partnerships
  3. 03FDA regulatory interactions - IND clearances for new programs, Fast Track or Orphan Drug designations
  4. 04Pipeline advancement milestones - patient enrollment completion, dose escalation decisions, expansion cohort initiations
  5. 05Competitive landscape shifts - rival programs showing superior efficacy or safety in similar indications
  6. 06No current revenue - pre-commercial clinical-stage company
  7. 07Future potential: licensing agreements or partnerships for pipeline assets
  8. 08Future potential: product sales upon regulatory approval (2028+ earliest scenario)
FY2025 Snapshot
Revenue
$0.00
NI Growth
-38.6%
EPS
$-0.63
1Y Return
-28.6%

HURA Chart

1.21.62.02.42.91.25HURA Daily1.25Jul '26Aug '26Oct '26Nov '26

My Notes

  • momentum/speculative - This is a binary-outcome, high-risk/high-reward clinical-stage play attracting biotech specialists…
  • Rising rates create significant headwinds through multiple channels: (1) higher discount rates compress NPV of distant future cash flows…
  • Watch on earnings: Monthly cash burn rate and ending cash balance - determines survival timeline, Clinical trial patient enrollment numbers and protocol amendments, Nasdaq minimum bid price compliance - stock below $1 risks delisting, further limiting financing options.

One Sentence Summary:

TuHURA Biosciences: the story is balanced — clinical trial data releases - particularly efficacy signals (orr, pfs) and safety profiles from ongoing phase 1/2 studies.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.